Advertisement
ViroPharma also announced that Robert Doody, manager, corporatecommunications of ViroPharma, will present at the Maxim Group GrowthConference at 10:30 A.M. ET on Tuesday, October 7, 2008. The conference isbeing held at the Grand Hyatt in New York.
Advertisement
William Roberts, vice president, corporate communications of ViroPharma,will present at the second annual Natixis Bleichroeder Hidden Gems Conferenceat 8:30 A.M. ET on Monday, October 13, 2008. The conference is being held atthe Waldorf=Astoria in New York.
ViroPharma's presentations will be webcast live for investors throughhttp://www.viropharma.com and available for a period of 14 days following theconferences.
About ViroPharma Incorporated
ViroPharma Incorporated is committed to the development andcommercialization of products that address serious diseases treated byphysician specialists and in hospital settings. ViroPharma commercializesVancocin(R) approved for oral administration for treatment ofantibiotic-associated pseudomembranous colitis caused by Clostridium difficileand enterocolitis caused by Staphylococcus aureus, includingmethicillin-resistant strains (for prescribing information, please downloadthe package insert at http://www.viropharma.com/Products.aspx). ViroPharmacurrently focuses its drug development activities in infectious diseasesincluding cytomegalovirus (CMV) and non-toxigenic C. difficile (NTCD).
SOURCE ViroPharma Incorporated
